Kidney cancer: Overall survival is an unsuitable primary end point

Nature Reviews Urology

Volumn 7, Issue 7, 2010, Pages 367-368

  Di Lorenzo, Giuseppe ^a   Buonerba, Carlo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; MAMMALIAN TARGET OF RAPAMYCIN; RECOMBINANT INTERFERON; SORAFENIB; SUNITINIB; VASCULOTROPIN;

CANCER GROWTH; CLINICAL TRIAL; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; METASTASIS; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SHORT SURVEY; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; HUMANS; KIDNEY NEOPLASMS; SURVIVAL RATE;

EID: 77954482008     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2010.84     Document Type: Short Survey

References (10)

1. Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584-3590 (2009).
2. Hudes, G. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007).
3. escudier, B. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase iii trial. Lancet 370, 2103-2111 (2007).
4. Rini, B. i. et al. Bevacizumab plus interferon alpha compared with interferon alpha monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 26, 5422-5428 (2008).
5. escudier, B. et al. sorafenib in advanced clearcell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007).
6. Motzer. R. J. et al. efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase iii trial. Lancet 372, 449-456 (2008).
7. sternberg, C. n. et al. A randomized, doubleblind phase iii study of pazopanib in treatmentnaive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC) [abstract 2347]. J. Clin. Oncol. 27 (15s), 5021 (2009).
8. Rini, B. et al. Phase iii trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol. 28, 2137-2143 (2010).
9. escudier, B. J. et al. Phase iii trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AvORen): final analysis of overall survival. J. Clin. Oncol. 28, 2144-2150 (2010).
10. Rini, B. et al. Hypertension (HTn) as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib [abstract 312]. AsCO 2010 Genitourinary Cancers symposium [online], http://www.asco.org/AsCOv2/ Meetings/ Abstracts?&vmview=abst-detail- view&confiD=73&abstractiD= 30099 (2010).